Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy

Leukemia

Volumn 28, Issue 5, 2014, Pages 1129-1131

  Thakurta, A ^a   Gandhi, A K ^a   Waldman, M F ^a   Bjorklund, C ^a   Ning, Y ^a   Mendy, D ^a   Schafer, P ^a   Lopez Girona, A ^a   Lentzsch, S ^b   Schey, S A ^c   Calle, Y ^c   Chelliah, R ^c   Orlowski, R Z ^d   Madan, A ^e   Avet Loiseau, H ^f   Chopra, R ^a  

^a CELGENE CORPORATION   (United States)

^b Department of Medicine College of Physicians and Surgeons Columbia University ^*  (United States)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e Covance Genomics Laboratory ^*  (United States)

^f TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LENALIDOMIDE; POMALIDOMIDE;

CANCER CELL LINE; CANCER IMMUNOTHERAPY; CEREBLON GENE; DNA DAMAGE BINDING PROTEIN 1 GENE; GENE EXPRESSION; GENE INTERACTION; GENE MUTATION; GENE SEQUENCE; GENE TARGETING; HEMATOLOGIC MALIGNANCY; HUMAN; LETTER; MANTLE CELL LYMPHOMA; MENTAL DEFICIENCY; MISSENSE MUTATION; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONSENSE MUTATION; ONCOGENE; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; DNA-BINDING PROTEINS; HUMANS; MUTATION; PEPTIDE HYDROLASES; THALIDOMIDE;

EID: 84899906409     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.315     Document Type: Letter

References (13)

1. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y. et al. Identification of a primary target of thalidomide teratogenicity. Science 2010; 327: 1345-1350.
2. Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van Wier S. et al. Cereblon expression is required for the anti-myeloma activity of lenalidomide and pomalidomide. Blood 2011; 118: 4771-4779.
3. Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J. et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 2012; 26: 2326-2335.
4. Broyl A, Kuiper R, van Duin M, van der Holt B, el Jarari L, Bertsch U. et al. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. Blood 2013; 121: 624-627.
5. Heintel D, Rocci A, Ludwig H, Bolomsky A, Caltagirone S, Schreder M. et al. High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone. Br J Haematol 2013; 161: 695-700.
6. Lode L, Amiot M, Maiga S, Touzeau C, Menard A, Magrangeas F. et al. Cereblon expression in multiple myeloma: Not ready for prime time. Br J Haematol 2013; 163: 282-284.
7. Schuster SR, Kortuem KM, Zhu XY, Braggio E, Shi CX, Bruins LA. et al. The clinical significance of cereblon in multiple myeloma. Leuk Res; e-pub ahead of print 5 September 2013; doi:10.1016/j.leukres.2013.08.015.
8. Higgins JJ, Pucilowska J, Lombardi RQ, Rooney JP. A mutation in a novel ATP-dependent Lon protease gene in a kindred with mild mental retardation. Neurology 2004; 63: 1927-1931.
9. Egan JB, Kortuem KM, Kurdoglu A, Izatt T, Aldrich J, Reiman R. et al. Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease. Br J Haematol 2013; 161: 748-751.
10. Sardnal V, Rouquette A, Kaltenbach S, Bally C, Chesnais V, Leschi C. et al. A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q). Leukemia 2013; 27: 1610-1613.
11. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC. et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011; 471: 467-472.
12. Gandhi AK, Avet-Loiseau H, Waldman M, Thakurta A, Aukerman SL, Chen G. et al. Detection and quantification of cereblon protein andmRNAinmultiplemyeloma cell lines and primary CD138+ multiple myeloma cells. Blood 2012; 120: (abstract 4043).
13. Gandhi AK, Mendy D, Waldman M, Chen G, Rychak E, Miller K. et al. Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity. Br J Haematol. e-pub ahead of print 28 October 2013, doi:10.1111/bjh.12622.